| pubmed-article:1419288 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1419288 | lifeskim:mentions | umls-concept:C0006413 | lld:lifeskim |
| pubmed-article:1419288 | lifeskim:mentions | umls-concept:C0033325 | lld:lifeskim |
| pubmed-article:1419288 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:1419288 | lifeskim:mentions | umls-concept:C0032854 | lld:lifeskim |
| pubmed-article:1419288 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:1419288 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1419288 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:1419288 | lifeskim:mentions | umls-concept:C0205099 | lld:lifeskim |
| pubmed-article:1419288 | lifeskim:mentions | umls-concept:C1561558 | lld:lifeskim |
| pubmed-article:1419288 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:1419288 | pubmed:dateCreated | 1992-12-4 | lld:pubmed |
| pubmed-article:1419288 | pubmed:abstractText | 14 adult patients between 16 and 50 years old with small non-cleaved cell lymphoma (Burkitt's lymphoma) were prospectively treated from 1982 to 1990 with the LMB protocols of the Société Française d'Oncologie Pédiatrique (SFOP). No HIV-positive patients were included. All patients had extensive disease with bad prognosis factors, i.e. 10 patients had Murphy stage III and 4 had stage IV with bone marrow involvement. The LMB protocols were characterised by high-dose fractionated cyclophosphamide, high-dose methotrexate (HD-MTX), and cytosine arabinoside. No local or central nervous system irradiation was used. Treatment duration ranged from 5 (LMB 84) to 12 (LMB 81) months. There were no therapy-related deaths. All patients achieved complete remission (CR). 6 patients relapsed between 2 and 30 months following CR. 8 of the 14 patients (57%) are still alive and disease-free after treatment by LMB protocol alone. 2 patients were salvaged with bone marrow transplantation after relapse and a total of 10 out of 14 patients (71%) are disease-free at the time of this report. Our results showed the high curability of advanced Burkitt's lymphoma using a paediatric protocol, even in adult patients. The LMB protocol may be applied to adult patients but requires intensive care during the induction period. | lld:pubmed |
| pubmed-article:1419288 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1419288 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1419288 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1419288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1419288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1419288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1419288 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1419288 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:SallesBB | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:PhilipTT | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:DemailleM CMC | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:BaillyCC | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:CarrieCC | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:ColombatPP | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:CahnJ YJY | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:DauriacCC | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:MeckenstockRR | lld:pubmed |
| pubmed-article:1419288 | pubmed:author | pubmed-author:DeconnickEE | lld:pubmed |
| pubmed-article:1419288 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1419288 | pubmed:volume | 28A | lld:pubmed |
| pubmed-article:1419288 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1419288 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1419288 | pubmed:pagination | 1954-9 | lld:pubmed |
| pubmed-article:1419288 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:meshHeading | pubmed-meshheading:1419288-... | lld:pubmed |
| pubmed-article:1419288 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1419288 | pubmed:articleTitle | Treatment of poor prognosis Burkitt's lymphoma in adults with the Société Française d'Oncologie Pédiatrique LMB Protocol--a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC). | lld:pubmed |
| pubmed-article:1419288 | pubmed:publicationType | Journal Article | lld:pubmed |
